CRL Earnings Prediction
The chart below shows how CRL performed 10 days before and after its earnings report, based on data from the past quarters. Typically, CRL sees a -0.01% change in stock price 10 days leading up to the earnings, and a +1.62% change 10 days following the report. On the earnings day itself, the stock moves by -0.58%. This data can give you a slight idea of what to expect for the next quarter's release.
CRL Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
1.00B
-1.08%
-0.71%
Gross Margin
27.77%
-16.43%
-16.38%
Operating Margin
9.00%
-39.31%
-38.61%
Net Margin
-21.32%
-214.38%
-406.32%
EPS
-4.22
-215.62%
-417.29%
No Data Available
CRL Earnings Analysis
Charles River Laboratories International Inc Corporation (CRL.N) Earnings Conference Call
Positive
Earnings Per Share Beat: Charles River Laboratories reported an EPS of $2.66, exceeding expectations of $2.50, indicating strong financial performance.
Fourth-Quarter Performance Boost: The company ended the year with fourth-quarter performance that was slightly better than expected, contributing to annual revenue and non-GAAP earnings per share that were higher than previously issued guidance.
Biopharmaceutical Demand Stability: Market trends for biopharmaceutical demand remain stable, with consistent DSA demand KPIs, including a stable net book-to-bill ratio, suggesting a positive outlook for 2025.
Global Biopharmaceutical Demand: The company is experiencing ongoing demand from global biopharmaceutical clients, which is expected to continue despite some restructuring and pipeline reprioritization activities.
Market Resilience and Growth: The management expressed confidence in the company's ability to navigate market challenges and maintain growth in the upcoming year.
Negative
Biopharmaceutical Client Restructuring: - The company noted that many global biopharmaceutical clients are undergoing restructuring and pipeline reprioritization, which is expected to constrain early-stage spending in 2025.
DSA Market Stability: - The demand for DSA (Discovery Services and Analytics) showed stable KPIs, but this stability may not translate into growth, indicating a lack of upward momentum in the market.
Challenging Market Environment: - The overall market environment remains challenging, with clients cautious about spending, which could impact future revenue growth.
Earnings Beat, Cautious Outlook: - Despite beating earnings expectations, the company highlighted that the market trends suggest a continued conservative approach from clients, which may affect future performance.
CRL FAQs
How does CRL typically perform around its earnings report dates?
Is Charles River Laboratories International Inc (CRL) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
CRL Earning Call Sentiment
Charles River Laboratories International, Inc. (NYSE:CRL) Q4 2024 Earnings Call Transcript
CRL.N
1.93%Positive
The earnings call summary presents a mixed outlook. While the company reported better-than-expected Q4 performance and raised EPS guidance, early-stage spending constraints and competitive pressures pose risks. The share repurchase program is a positive, but stable demand KPIs and cautious client activities suggest limited growth. The Q&A section did not reveal significant new insights, and management's cautious tone on future demand and restructuring impacts suggests a neutral sentiment. Overall, the stock price is likely to remain stable over the next two weeks.
